Drug Profile
Rivogenlecleucel - Bellicum Pharmaceuticals
Alternative Names: Allogeneic polyclonal T-cells - Bellicum Pharmaceuticals; BPX-501; BPX-501 and AP1903; BPX-501-AP1903; BPX-501-rimiducid; BPX-501-T-cells; CaspaCIDe® DLI; Rimiducid activated BPX 501; Rivo-cel; Rivo-cel - Bellicum PharmaceuticalsLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Bellicum Pharmaceuticals
- Class Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Haematological malignancies; Haemoglobinopathies; Immunodeficiency disorders; Immunological disorders; Metabolic disorders; Myelodysplastic syndromes
Most Recent Events
- 05 Apr 2024 Discontinued - Phase-I for Haemoglobinopathies (In adolescents, In children, In infants, In adults) in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
- 08 Mar 2024 Bellicum Pharmaceuticals terminates a phase I/II follow-up trial in Haematological malignancies (In infants, In children, In adolescents, In adults) in Italy (IV, Infusion) due to unknown reasons, before March 2024 (EudraCT2016-003226-16)
- 23 Feb 2024 Discontinued - Phase-I for Haematological malignancies (In adolescents, In children, In the elderly, In infants, Second-line therapy or greater, In adults) in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active